Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axogen Inc (NQ: AXGN )

13.79 -0.01 (-0.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 265,407
Open 13.98
Bid (Size) 13.77 (20)
Ask (Size) 13.78 (1)
Prev. Close 13.80
Today's Range 13.58 - 14.06
52wk Range 3.450 - 15.08
Shares Outstanding 41,397,053
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®
From Axogen, Inc.
Via GlobeNewswire
Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4)
From Axogen, Inc.
Via GlobeNewswire

Performance

YTD
+99.57%
+99.57%
1 Month
+8.50%
+8.50%
3 Month
+91.00%
+91.00%
6 Month
+70.88%
+70.88%
1 Year
+175.80%
+175.80%

More News

Read More
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
From CytoSorbents
Via GlobeNewswire
Axogen Earnings Preview
Via Benzinga
AXGN Stock Earnings: Axogen Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Parker-Hannifin Posts Upbeat Earnings, Joins Under Armour, Zillow Group, YETI Holdings, Eli Lilly And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Axogen, Inc. Announces New Leadership Appointments
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. Reports Second Quarter 2024 Financial Results
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
From Axogen, Inc.
Via GlobeNewswire
Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™
From Axogen, Inc.
Via GlobeNewswire
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
From Axogen, Inc.
Via GlobeNewswire
Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
From Axogen, Inc.
Via GlobeNewswire
AXGN Stock Earnings: Axogen Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Axogen, Inc Reports First Quarter 2024 Financial Results
From Axogen, Inc.
Via GlobeNewswire
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
From Axogen, Inc.
Via GlobeNewswire
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
AXGN Stock Earnings: Axogen Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
From Axogen, Inc.
Via GlobeNewswire
Earnings Scheduled For March 5, 2024
Via Benzinga
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
From Axogen, Inc.
Via GlobeNewswire
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
From Axogen, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.